Cha Ra Ri, Sonu Irene
Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Clin Endosc. 2025 May;58(3):352-359. doi: 10.5946/ce.2024.270. Epub 2025 Mar 25.
Fecal microbiota transplantation (FMT) involves transplanting fecal matter from healthy donors into patients with gut dysbiosis to restore microbial balance. It has been proven to be highly effective in treating recurrent Clostridioides difficile infection (CDI), and United States Food and Drug Administration-approved microbiome-based therapies, such as REBYOTA (fecal microbiota live-jslm) and VOWST (fecal microbiota spores live-brpk), offer promising treatment options. Although FMT is widely used to treat recurrent CDI, its use in gastrointestinal and metabolic diseases remains limited. Future research directions include optimizing donor selection, understanding microbial mechanisms, and exploring the potential of FMT for treating other diseases. Ongoing research not only aims to broaden its indications but also improves its safety and efficacy. Emerging therapies such as VE303 (Vedanta) are being studied to refine treatment approaches and expand the use of microbiota-based therapies. Further studies are needed to standardize guidelines, improve patient outcomes, and better define the role of FMT in the treatment of diseases beyond recurrent CDI.
粪便微生物群移植（FMT）是将健康供体的粪便物质移植到肠道生态失调的患者体内，以恢复微生物平衡。事实证明，它在治疗复发性艰难梭菌感染（CDI）方面非常有效，并且美国食品药品监督管理局批准的基于微生物群的疗法，如REBYOTA（活粪微生物群-jslm）和VOWST（活粪微生物群孢子-brpk），提供了有前景的治疗选择。尽管FMT被广泛用于治疗复发性CDI，但其在胃肠道和代谢疾病中的应用仍然有限。未来的研究方向包括优化供体选择、理解微生物机制以及探索FMT治疗其他疾病的潜力。正在进行的研究不仅旨在扩大其适应症，还旨在提高其安全性和有效性。正在研究诸如VE303（韦丹塔）等新兴疗法，以完善治疗方法并扩大基于微生物群的疗法的应用。需要进一步研究来规范指南、改善患者预后，并更好地界定FMT在复发性CDI以外疾病治疗中的作用。
